TVTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Travere Therapeutics Inc (TVTX) shows positive momentum in technical indicators and analyst ratings, but the overbought RSI and lack of strong proprietary trading signals suggest caution for a beginner, long-term investor. While the stock has potential, it may not be the best entry point currently due to its overbought status and potential short-term pullback.
The MACD is positive and expanding, indicating bullish momentum. The RSI is at 80.931, signaling an overbought condition. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level of 50.617, with resistance levels at 54.701 and 57.224. However, the overbought RSI suggests potential for a short-term pullback.
Analysts have consistently raised price targets, with the latest target at $70, reflecting confidence in the company's growth potential.
The company's pipeline expansion and patent extensions for Filspari strengthen its market position.
Positive sentiment around its rare kidney disease franchise and recent licensing agreements.
The RSI indicates the stock is overbought, which may lead to a short-term pullback.
No recent significant hedge fund or insider trading activity to support strong buying sentiment.
Stock trend analysis suggests a potential decline in the next week (-3.87%) and month (-9.36%).
No financial data available for the latest quarter.
Analysts are overwhelmingly positive on the stock, with multiple firms raising price targets recently. The consensus is a Buy rating, with the highest target at $70, reflecting confidence in the company's growth trajectory and strategic moves.
